PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.83%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.83%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-9.09%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.06%
Share count expansion well above GNPX's 0.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above GNPX's 0.19%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-120.93%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.56%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
77.71%
3Y OCF/share CAGR above 1.5x GNPX's 24.32%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
99.67%
Net income/share CAGR above 1.5x GNPX's 62.82% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
85.97%
Positive 5Y CAGR while GNPX is negative. John Neff might view this as a strong mid-term relative advantage.
69.72%
3Y net income/share CAGR above 1.5x GNPX's 16.04%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
173.45%
Equity/share CAGR of 173.45% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-62.01%
Negative 5Y equity/share growth while GNPX is at 662.87%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
56.61%
Below 50% of GNPX's 156.46%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-13.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.77%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
45.24%
R&D growth drastically higher vs. GNPX's 22.77%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-4.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.